AcroMetrix is a medical technologies company that specializes in offering a full range of molecular products that are designed to meet specific needs of the medical testing community. They currently operate out of facilities located in Benicia, California and Alkmaar, the Netherlands.
AcroMetrix primarily develops products for medical testing, which include controls and standards that assist the implementation and monitoring of diagnostic assays for clinical laboratories, blood centers and manufactures. Because of their research and development of new, critical technologies, AcroMetrix has grown to become one of the leading manufacturers of molecular quality control standards, as well as controls used for clinical diagnosis and blood testing laboratories.
The company recently released a new qualification panel called the OptiQuant-S HCV RNA Qualification Panel. This panel uses AcroMetrix’s proprietary technology known as SynTura™, which will give labs a new way to better optimize the Hepatitis C molecular assays currently in use.
Today, viral Hepatitis C and B comprise more than 75% of all cases of liver disease around the globe. Physicians routinely monitor their 1 HCV patients to diagnose changes in the amount of virus in the patient’s system (commonly known as viral load.) It is crucial that doctors get an accurate viral load reading from testing in order to adjust treatment and drug therapy as needed.
Michael Eck, President and CEO of AcroMetrix recently said, “OptiQuant-S HCV represents our continued commitment to Hepatitis C diagnostic testing. Medical laboratories utilizing the new OptiQuant-S HCV Panel will experience the benefits of a standardized product that offers consistent results with an enhanced dynamic range; and as a result reducing patient re-testing requirements and increasing savings in both labor and reagent costs.”
One of the aspects that makes the SynTura™ Technology a big deal is that it involves second generation viral RNA material that responds much like enveloped mammalian RNA viruses such as HCV or HIV. What this means is that researchers will be able to easily insert synthetic sequences into mammalian RNA viruses that are shown to be stable in replication and able to form RNase resistant virus particles. Researchers can then develop and design defined RNA positive controls, quantification standards, internal controls and calibrators.
If you’d like to learn more about this exciting new technology, or about AcroMetrix in general, feel free to visit their website at www.acrometrix.com.
Additional Resources:
Acrometrix Homepage
Acrometrix On Directorygiant.com
Acrometrix On EveryonesArticles.com
Acrometrix On DTList
Acrometrix Profile My Opera
Acrometrix iLand